Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
España
India
Italia
대한민êµ
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민êµ
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Nuvectis Pharma
NVCT
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$6.45
-0.05
-0.77%
At Close: -
$6.34
-0.11
-1.71%
After Hours: 7:00 AM EDT
15 minutes delayed
Get Report
Comment
Nuvectis Pharma (NVCT) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Nuvectis Pharma (NASDAQ:NVCT) Stock
Nuvectis Pharma Stock (NASDAQ: NVCT)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, August 29, 2024
Nuvectis Pharma Receives Orphan Drug Designat...
Benzinga Newsdesk
Tuesday, August 06, 2024
HC Wainwright & Co. Reiterates Buy on Nuvecti...
Benzinga Newsdesk
Nuvectis Pharma Q2 EPS $(0.26), Inline
Benzinga Newsdesk
Wednesday, May 08, 2024
HC Wainwright & Co. Reiterates Buy on Nuvecti...
Benzinga Newsdesk
Tuesday, May 07, 2024
Nuvectis Pharma Q1 EPS $(0.25) Beats $(0.40) ...
Benzinga Newsdesk
Monday, April 08, 2024
Nuvectis Pharma's NXP900 Demonstrates Robust ...
Benzinga Newsdesk
Thursday, March 14, 2024
Nuvectis Pharma Announced 33% Response Rate A...
Benzinga Newsdesk
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
Nuvectis Pharma Announces Preliminary Data Fr...
Benzinga Newsdesk
Tuesday, March 05, 2024
Nuvectis Pharma, Inc. Reports Fiscal Year 202...
Benzinga Newsdesk
Thursday, January 18, 2024
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
Monday, December 18, 2023
Nuvectis Pharma, Inc. Announces A Collaborati...
Benzinga Newsdesk
Wednesday, November 08, 2023
Nuvectis Pharma Q3 EPS $(0.37) Misses $(0.34)...
Benzinga Newsdesk
Recap: Nuvectis Pharma Q3 Earnings
Benzinga Insights
Tuesday, October 17, 2023
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
Thursday, September 21, 2023
Nuvectis Pharma Announces Upcoming Presentati...
Benzinga Newsdesk
Friday, September 15, 2023
HC Wainwright & Co. Reiterates Buy on Nuvecti...
Benzinga Newsdesk
Tuesday, September 12, 2023
Nuvectis Pharma Initiates NXP900 Phase 1a Cli...
Benzinga Newsdesk
Thursday, August 17, 2023
The FDA Has Granted Orphan Drug Designation T...
Benzinga Newsdesk
Monday, August 14, 2023
10 Short Squeeze Stocks To Watch: Blue Apron, Intuitive Machines, Yellow Corp, Getty Images And More
Chris Katje
Wednesday, August 09, 2023
Nuvectis Pharma Q2 EPS $(0.38) Misses $(0.29)...
Benzinga Newsdesk
Friday, July 28, 2023
Insiders Buying Texas Capital Bancshares And 3 Other Stocks
Lisa Levin
Tuesday, July 25, 2023
10% Owner of Nuvectis Pharma Purchased $119K In Stock
Benzinga Insights
Friday, July 21, 2023
Insiders Buying Steel Connect And 2 Other Stocks
Lisa Levin
Thursday, July 20, 2023
10% Owner At This Health Care Company Buys $135K of Stock
Benzinga Insights
Nuvectis Pharma 10% Owner Trades $118K In Company Stock
Benzinga Insights
Insiders Buying Nuvectis Pharma And 2 Other Stocks
Lisa Levin
Wednesday, July 19, 2023
Nuvectis Pharma 10% Owner Trades Company's Stock
Benzinga Insights
Insiders Buying Joint Corp And 2 Other Stocks
Lisa Levin
Friday, July 14, 2023
Insiders Buying BranchOut Food And 2 Other Stocks
Lisa Levin
Thursday, July 13, 2023
10% Owner of Nuvectis Pharma Makes $153K Buy
Benzinga Insights
Insiders Buying Asana And 2 Other Stocks
Lisa Levin
Wednesday, July 12, 2023
10% Owner of Nuvectis Pharma Makes $153K Buy
Benzinga Insights
Tuesday, July 11, 2023
10% Owner At This Health Care Company Buys $135K of Stock
Benzinga Insights
More Than $3M Bet On Asana? Check Out These 3 Stocks Insiders Are Buying
Lisa Levin
Monday, July 10, 2023
Nuvectis Pharma Insider Trades Send a Signal
Benzinga Insights
Friday, July 07, 2023
$1M Bet On Children's Place? Check Out These 3 Stocks Insiders Are Buying
Lisa Levin
Monday, June 26, 2023
Nuvectis Pharma 10% Owner Makes $1.28M Stock Purchase
Benzinga Insights
Tuesday, June 20, 2023
Nuvectis Pharma Set To Join Russell 2000 And ...
Benzinga Newsdesk
Over $2M Bet On This Financial Services Stock? Check Out These 3 Stocks Insiders Are Buying
Lisa Levin
Monday, May 15, 2023
Nuvectis Pharma Announces FDA Clearance Of NX...
Benzinga Newsdesk
Wednesday, May 10, 2023
Nuvectis Pharma: Q1 Earnings Insights
Benzinga Insights
Nuvectis Pharma Q1 EPS $(0.27) Beats $(0.44) ...
Benzinga Newsdesk
Monday, April 10, 2023
Nuvectis Pharma Initiates Phase 1b Study For ...
Benzinga Newsdesk
Friday, March 17, 2023
Nuvectis Pharma Announces Upcoming Presentati...
Benzinga Newsdesk
Tuesday, March 07, 2023
HC Wainwright & Co. Reiterates Buy on Nuvecti...
Benzinga Newsdesk
Nuvectis Pharma FY22 EPS $(1.51)
Benzinga Newsdesk
Friday, February 10, 2023
HC Wainwright & Co. Reiterates Buy on Nuvecti...
Benzinga Newsdesk
Thursday, February 09, 2023
Nuvectis Pharma Announces A Publication In The Journal Of Experimental Medicine For NXP900 In An In-Vivo Model Of Metastatic Castration Resistant Prostate Cancer With Acquired Resistance To Enzalutamide, The Active Ingredient In Xtandi
Happy Mohamed
Wednesday, January 04, 2023
Nuvectis Pharma Announces Collaboration With ...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch